TECHNETIUM TC 99M SESTAMIBI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Technetium Tc 99m Sestamibi, and when can generic versions of Technetium Tc 99m Sestamibi launch?
Technetium Tc 99m Sestamibi is a drug marketed by Cardinal Health 414, Curium, Jubilant Draximage, and Sun Pharm Inds Inc. and is included in four NDAs.
The generic ingredient in TECHNETIUM TC 99M SESTAMIBI is technetium tc-99m sestamibi kit. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the technetium tc-99m sestamibi kit profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TECHNETIUM TC 99M SESTAMIBI?
- What are the global sales for TECHNETIUM TC 99M SESTAMIBI?
- What is Average Wholesale Price for TECHNETIUM TC 99M SESTAMIBI?
Summary for TECHNETIUM TC 99M SESTAMIBI
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 10 |
| Clinical Trials: | 7 |
| DailyMed Link: | TECHNETIUM TC 99M SESTAMIBI at DailyMed |
Recent Clinical Trials for TECHNETIUM TC 99M SESTAMIBI
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| M.D. Anderson Cancer Center | Early Phase 1 |
| National Cancer Institute (NCI) | Early Phase 1 |
| GE Healthcare | Early Phase 1 |
Pharmacology for TECHNETIUM TC 99M SESTAMIBI
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |

